Welcome to our dedicated page for Kezar Life Sciences news (Ticker: KZR), a resource for investors and traders seeking the latest updates and insights on Kezar Life Sciences stock.
Kezar Life Sciences, Inc. has reported developments tied to its history as a clinical-stage biopharmaceutical company developing small molecule therapeutics for immune-mediated diseases. Company updates have centered on zetomipzomib, a selective immunoproteasome inhibitor evaluated in autoimmune hepatitis and other chronic immune-mediated diseases, including clinical data presentations and FDA regulatory correspondence.
Other recurring developments include operating and financial results, cost-containment measures, strategic review actions, the completed sale of Sec61-based discovery and development assets including KZR-261 to Enodia Therapeutics, and corporate transaction matters following Aurinia-related acquisition activity and Nasdaq delisting procedures.
Kezar Life Sciences, Inc. (Nasdaq: KZR) announced promising results from its Phase 1b study of KZR-616 for treating systemic lupus erythematosus (SLE) and lupus nephritis. Among two lupus nephritis patients, both experienced over 50% reduction in proteinuria. Overall, the study showed improvements in seven disease activity measures, indicating positive exploratory efficacy data. The safety profile of KZR-616 was favorable, with no treatment discontinuations reported. Encouraged by the results, Kezar aims to expedite the development of KZR-616 for severe autoimmune diseases.
Kezar Life Sciences announced that its executive team will participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 1:30 PM EDT. The event will be accessible via live webcast through the company's website, with an archived replay available for 90 days post-conference. Kezar focuses on innovative therapies for autoimmune diseases and cancer, with candidates like KZR-616 and KZR-261 in development.
Kezar Life Sciences (Nasdaq: KZR) announced significant presentations at major upcoming scientific conferences, highlighting their innovative therapeutic programs. Three abstracts have been accepted, showcasing the preclinical data for KZR-261 targeting solid tumors and the promising clinical data for KZR-616 in treating severe autoimmune diseases. Notably, these presentations include details about clinical trials and findings that underscore the potential of these compounds in their respective therapeutic areas.
Kezar Life Sciences (KZR) announced key updates in its Q1 2020 financial results and corporate activities. Noreen R. Henig, MD, has been appointed as Chief Medical Officer, enhancing the leadership team. The company reported cash and equivalents of $123 million as of March 31, 2020, a notable increase from $78.2 million in Q4 2019. Ongoing clinical trials for KZR-616 are active, despite anticipated delays due to COVID-19. Additionally, KZR-261's IND submission is on track for Q1 2021, with new data presentation planned at ASCO 2020.
Kezar Life Sciences (KZR) announced the appointment of Dr. Noreen R. Henig as Chief Medical Officer on May 4, 2020. Dr. Henig brings extensive experience in clinical development and medical affairs, having previously served as CMO at Breath Therapeutics and ProQR Therapeutics. Her role will involve overseeing clinical development and regulatory aspects at Kezar, which focuses on novel therapeutics for autoimmune diseases and cancer. CEO John Fowler praised her leadership and expertise in immunology, indicating her potential to positively influence the company's growth and patient engagement.